Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Lacosamide (Vimpat®)
Indication under review	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-16 years) patients with epilepsy
Policy No:	APC 142
Date of Issue:	January 2017
Review Date:	January 2020

Policy Statement:
Lacosamide (Vimpat®) is approved for use as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescent patients with epilepsy who have been refractory to other treatment strategies.

Traffic Light Status	**Amber**

Key Points considered:

- Lacosamide can be considered as an add on therapy for patients who are already taking first line drugs (typically carbamazepine, sodium valproate or lamotrigine) who have continuing seizures despite adequate trials of other secondary or third line drugs.
- The evidence for the efficacy of lacosamide was considered to be relatively strong, based on three double-blind, randomised controlled trials (RCTs) comparing lacosamide with placebo. Compared with placebo, treatment with lacosamide 400 mg/day was associated with a greater decrease in seizure frequency, with a higher proportion of patients experiencing at least a 50% decrease in seizure frequency; evidence for efficacy was weaker for the 200 mg/day dose.
- As a number of established alternative therapies exist, lacosamide is considered to have a relatively low place in therapy.
- Initiation of treatment must be by a consultant neurologist.

Date taken to APC:	11th January 2017
Date Ratified by GPMOC on Behalf of the Board:	18th January 2017